Specifically, MOC31PE, composed of EpCAM antibody and the complete Pseudomonas exotoxin A (PE), has shown significant survival extension in patients with metastatic CRC when used as a monotherapy, and has also been shown to provoke antitumor immunity through the induction of ICD However, the potential of toxin delivery with CDH17 targeting in CRC remains to be investigated. The gene discussed is CDH17; the disease is colorectal carcinoma.